MedDataX Logo

Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension

NCT ID: NCT00926289

Last Updated: 2014-06-27

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

894 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this trial is to demonstrate that the fixed-dose combination of T80/HCTZ25 is superior as first line therapy in reducing seated trough cuff Systolic Blood Pressure(SBP) compared to the monotherapy of T80 in patients with grade 2 or grade 3 hypertension (SBP\>=160 mmHg and Diastolic Blood Pressure(DBP)\>=100 mmHg).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Telmisartan80/HCTZ25 Versus Telmisartan80/HCTZ12.5 in Hypertension Not Responding to Telmisartan80/HCTZ12.5

NCT00239369

Hypertension
COMPLETED PHASE3

Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension

NCT00326768

Hypertension
COMPLETED PHASE3

Open-label Follow-up Trial of Fixed Dose Combination of Telmisartan + Hydrochlorothiazide in Hypertensive Patients

NCT00267943

Hypertension
COMPLETED PHASE3

Telmisartan With or Without Hydrochlorothiazide in Patients With Mild-to-moderate Hypertension

NCT02177435

Hypertension
COMPLETED PHASE3

Telmisartan Plus Hydrochlorothiazide in Subjects With Mild-to-moderate Hypertension Who Failed to Respond to Telmisartan Monotherapy

NCT02177500

Hypertension
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Telmisartan

Telmisartan 80 mg

Group Type ACTIVE_COMPARATOR

Telmisartan

Intervention Type DRUG

Telmisartan 80mg

Telmisartan/hydrochlorothiazide

Telmisartan80mg/Hydrochlorothiazide25mg

Group Type EXPERIMENTAL

Telmisartan

Intervention Type DRUG

Telmisartan 80mg

Hydrochlorothiazide

Intervention Type DRUG

Hydrochlorothiazide25mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Telmisartan

Telmisartan 80mg

Intervention Type DRUG

Telmisartan

Telmisartan 80mg

Intervention Type DRUG

Hydrochlorothiazide

Hydrochlorothiazide25mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Ability to provide written informed consent in accordance with Good Clinical Practice and local legislation;
2. Age 18 years or older;
3. Patients with grade 2 or grade 3 hypertension as defined SBP\>=160 mmHg and DBP\>=100 mmHg at randomization
4. Ability to stop any current antihypertensive therapy without unacceptable risk to the patient (Investigator's discretion)

Exclusion Criteria

1. Pre-menopausal women (last menstruation \<=1 year prior to signing informed consent) who: a) are not surgically sterile; or b) are nursing, or c) are pregnant, or d) are of childbearing potential and are NOT practicing acceptable methods of birth control, or do NOT plan to continue practicing an acceptable method throughout the trial. The only acceptable methods of birth control are: Intra-Uterine Device (IUD), Oral contraceptives, Implantable or injectable contraceptives, Estrogen patch Hormonal birth control should have been in use for at least three months before the study and continue at least until the next menstrual period after completing the study.
2. Night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4:00 a.m.
3. Known or suspected secondary hypertension (e.g., renal artery stenosis orphaeochromocytoma)
4. Mean in-clinic seated cuff SBP\>= 200 mmHg and/or DBP \>=120 mmHg
5. Renal dysfunction as defined by the following laboratory parameters: Serum creatinine \>3.0 mg/dL (or \>265 umol/L) and/or known creatinine clearance of \<30 ml/min and/or clinical markers of severe renal impairment.
6. Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant patients or patients with only one kidney
7. Clinically relevant hypokalemia or hyperkalemia (i.e., \<3.5 mmol/L or \>5.5 mmol/L, may be rechecked for suspected error in result)
8. Uncorrected sodium or volume depletion
9. Primary aldosteronism.
10. Hereditary fructose intolerance
11. Biliary obstructive disorders (e.g., cholestasis) or hepatic insufficiency
12. Congestive heart failure New York Heart Association functional class Congestive Heart Failure III-IV (Refer to Appendix 10.3)
13. Contra-indication to a placebo run-in period (e.g., stroke with-in the past 6 months, myocardial infarction, cardiac surgery, percutaneous transluminal coronary angioplasty, unstable angina or coronary artery bypass graft within the past 3 months prior to start of run in period)
14. Clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the Investigator
15. Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve
16. Patients whose diabetes has not been stable and controlled for at least the past 3 months as defined by an Glycosylated Hemoglobin \>=10%
17. Patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin-II receptor antagonists
18. History of drug or alcohol dependency within 6 months prior to signing the informed consent form
19. Concomitant administration of any medications known to affect blood pressure, except medications allowed by the protocol
20. Any investigational drug therapy within 1 month of signing the informed consent
21. Known hypersensitivity to any component of the trial drugs (telmisartan, hydrochlorothiazide, or placebo)
22. History of non-compliance or inability to comply with prescribed medications or protocol procedures (less than 80% or more than 120%, especially during run-in)
23. Any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of the trial medication
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Boehringer Ingelheim

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

502.550.01008 Boehringer Ingelheim Investigational Site

Athens, Alabama, United States

Site Status

502.550.01019 Boehringer Ingelheim Investigational Site

Mobile, Alabama, United States

Site Status

502.550.01015 Boehringer Ingelheim Investigational Site

Lomita, California, United States

Site Status

502.550.01003 Boehringer Ingelheim Investigational Site

Colorado Springs, Colorado, United States

Site Status

502.550.01014 Boehringer Ingelheim Investigational Site

Fort Lauderdale, Florida, United States

Site Status

502.550.01002 Boehringer Ingelheim Investigational Site

Louisville, Kentucky, United States

Site Status

502.550.01011 Boehringer Ingelheim Investigational Site

New Iberia, Louisiana, United States

Site Status

502.550.01009 Boehringer Ingelheim Investigational Site

New Orleans, Louisiana, United States

Site Status

502.550.01018 Boehringer Ingelheim Investigational Site

Olive Branch, Mississippi, United States

Site Status

502.550.01006 Boehringer Ingelheim Investigational Site

St Louis, Missouri, United States

Site Status

502.550.01016 Boehringer Ingelheim Investigational Site

Charlotte, North Carolina, United States

Site Status

502.550.01007 Boehringer Ingelheim Investigational Site

Greensboro, North Carolina, United States

Site Status

502.550.01005 Boehringer Ingelheim Investigational Site

Cincinnati, Ohio, United States

Site Status

502.550.01001 Boehringer Ingelheim Investigational Site

Cleveland, Ohio, United States

Site Status

502.550.01017 Boehringer Ingelheim Investigational Site

Houston, Texas, United States

Site Status

502.550.01020 Boehringer Ingelheim Investigational Site

Houston, Texas, United States

Site Status

502.550.01012 Boehringer Ingelheim Investigational Site

San Antonio, Texas, United States

Site Status

502.550.01004 Boehringer Ingelheim Investigational Site

Arlington, Virginia, United States

Site Status

502.550.35901 Boehringer Ingelheim Investigational Site

Sofia, , Bulgaria

Site Status

502.550.35902 Boehringer Ingelheim Investigational Site

Sofia, , Bulgaria

Site Status

502.550.35903 Boehringer Ingelheim Investigational Site

Sofia, , Bulgaria

Site Status

502.550.35904 Boehringer Ingelheim Investigational Site

Sofia, , Bulgaria

Site Status

502.550.35905 Boehringer Ingelheim Investigational Site

Sofia, , Bulgaria

Site Status

502.550.35908 Boehringer Ingelheim Investigational Site

Sofia, , Bulgaria

Site Status

502.550.35909 Boehringer Ingelheim Investigational Site

Sofia, , Bulgaria

Site Status

502.550.35910 Boehringer Ingelheim Investigational Site

Sofia, , Bulgaria

Site Status

502.550.35911 Boehringer Ingelheim Investigational Site

Sofia, , Bulgaria

Site Status

502.550.35906 Boehringer Ingelheim Investigational Site

Stara Zagora, , Bulgaria

Site Status

502.550.86004 Boehringer Ingelheim Investigational Site

Changsha, , China

Site Status

502.550.86003 Boehringer Ingelheim Investigational Site

Guangzhou, Guangdong Province, , China

Site Status

502.550.86008 Boehringer Ingelheim Investigational Site

Qingdao, , China

Site Status

502.550.86001 Boehringer Ingelheim Investigational Site

Shanghai, , China

Site Status

502.550.86002 Boehringer Ingelheim Investigational Site

Shanghai, , China

Site Status

502.550.86009 Boehringer Ingelheim Investigational Site

Shenyang, , China

Site Status

502.550.86007 Boehringer Ingelheim Investigational Site

Tianjin, , China

Site Status

502.550.86010 Boehringer Ingelheim Investigational Site

Zhengzhou, , China

Site Status

502.550.3302D Boehringer Ingelheim Investigational Site

Aigrefeuille S/Maine, , France

Site Status

502.550.3305I Boehringer Ingelheim Investigational Site

Aix-en-Provence, , France

Site Status

502.550.3305G Boehringer Ingelheim Investigational Site

Aubagne, , France

Site Status

502.550.3301H Boehringer Ingelheim Investigational Site

Briollay, , France

Site Status

502.550.3301K Boehringer Ingelheim Investigational Site

Cholet, , France

Site Status

502.550.3302I Boehringer Ingelheim Investigational Site

Corsept, , France

Site Status

502.550.3302C Boehringer Ingelheim Investigational Site

Donges, , France

Site Status

502.550.3302B Boehringer Ingelheim Investigational Site

La Montagne, , France

Site Status

502.550.3306A Boehringer Ingelheim Investigational Site

Louvigné-de-Bais, , France

Site Status

502.550.3303A Boehringer Ingelheim Investigational Site

Marseille, , France

Site Status

502.550.3303D Boehringer Ingelheim Investigational Site

Marseille, , France

Site Status

502.550.3303F Boehringer Ingelheim Investigational Site

Marseille, , France

Site Status

502.550.3304A Boehringer Ingelheim Investigational Site

Marseille, , France

Site Status

502.550.3304D Boehringer Ingelheim Investigational Site

Marseille, , France

Site Status

502.550.3304F Boehringer Ingelheim Investigational Site

Marseille, , France

Site Status

502.550.3304J Boehringer Ingelheim Investigational Site

Marseille, , France

Site Status

502.550.3305A Boehringer Ingelheim Investigational Site

Marseille, , France

Site Status

502.550.3301A Boehringer Ingelheim Investigational Site

Mûrs-Erigné, , France

Site Status

502.550.3301I Boehringer Ingelheim Investigational Site

Mûrs-Erigné, , France

Site Status

502.550.3302A Boehringer Ingelheim Investigational Site

Nantes, , France

Site Status

502.550.3302E Boehringer Ingelheim Investigational Site

Nantes, , France

Site Status

502.550.3301E Boehringer Ingelheim Investigational Site

Parçay-les-Pins, , France

Site Status

502.550.3303C Boehringer Ingelheim Investigational Site

Roquevaire, , France

Site Status

502.550.3302G Boehringer Ingelheim Investigational Site

Saint Aubin Les Châteaux, , France

Site Status

502.550.3306F Boehringer Ingelheim Investigational Site

Saint-Jouan-des-Guérets, , France

Site Status

502.550.3301F Boehringer Ingelheim Investigational Site

Segré, , France

Site Status

502.550.3307A Boehringer Ingelheim Investigational Site

Thouars, , France

Site Status

502.550.3301J Boehringer Ingelheim Investigational Site

Vihiers, , France

Site Status

502.550.99501 Boehringer Ingelheim Investigational Site

Tbilisi, , Georgia

Site Status

502.550.99502 Boehringer Ingelheim Investigational Site

Tbilisi, , Georgia

Site Status

502.550.99503 Boehringer Ingelheim Investigational Site

Tbilisi, , Georgia

Site Status

502.550.99504 Boehringer Ingelheim Investigational Site

Tbilisi, , Georgia

Site Status

502.550.99505 Boehringer Ingelheim Investigational Site

Tbilisi, , Georgia

Site Status

502.550.99506 Boehringer Ingelheim Investigational Site

Tbilisi, , Georgia

Site Status

502.550.99507 Boehringer Ingelheim Investigational Site

Tbilisi, , Georgia

Site Status

502.550.99508 Boehringer Ingelheim Investigational Site

Tbilisi, , Georgia

Site Status

502.550.40002 Boehringer Ingelheim Investigational Site

Baia Mare Maramures, , Romania

Site Status

502.550.40003 Boehringer Ingelheim Investigational Site

Brăila, , Romania

Site Status

502.550.40001 Boehringer Ingelheim Investigational Site

Bucharest, , Romania

Site Status

502.550.40010 Boehringer Ingelheim Investigational Site

Bucharest, , Romania

Site Status

502.550.40012 Boehringer Ingelheim Investigational Site

Bucharest, , Romania

Site Status

502.550.40009 Boehringer Ingelheim Investigational Site

Cluj-Napoca, , Romania

Site Status

502.550.40011 Boehringer Ingelheim Investigational Site

Cluj-Napoca, , Romania

Site Status

502.550.40006 Boehringer Ingelheim Investigational Site

Iași, , Romania

Site Status

502.550.40004 Boehringer Ingelheim Investigational Site

Oradea, , Romania

Site Status

502.550.40005 Boehringer Ingelheim Investigational Site

Sibiu, , Romania

Site Status

502.550.40008 Boehringer Ingelheim Investigational Site

Tg. Mures, , Romania

Site Status

502.550.07001 Boehringer Ingelheim Investigational Site

Moscow, , Russia

Site Status

502.550.07002 Boehringer Ingelheim Investigational Site

Moscow, , Russia

Site Status

502.550.07003 Boehringer Ingelheim Investigational Site

Moscow, , Russia

Site Status

502.550.07004 Boehringer Ingelheim Investigational Site

Moscow, , Russia

Site Status

502.550.07005 Boehringer Ingelheim Investigational Site

Moscow, , Russia

Site Status

502.550.07006 Boehringer Ingelheim Investigational Site

Moscow, , Russia

Site Status

502.550.07007 Boehringer Ingelheim Investigational Site

Saint Petersburg, , Russia

Site Status

502.550.07008 Boehringer Ingelheim Investigational Site

Saint Petersburg, , Russia

Site Status

502.550.07009 Boehringer Ingelheim Investigational Site

Saint Petersburg, , Russia

Site Status

502.550.07010 Boehringer Ingelheim Investigational Site

Saint Petersburg, , Russia

Site Status

502.550.82008 Boehringer Ingelheim Investigational Site

Cheonan, , South Korea

Site Status

502.550.82009 Boehringer Ingelheim Investigational Site

Daegu, , South Korea

Site Status

502.550.82001 Boehringer Ingelheim Investigational Site

Goyang, , South Korea

Site Status

502.550.82003 Boehringer Ingelheim Investigational Site

Gwangju, , South Korea

Site Status

502.550.82002 Boehringer Ingelheim Investigational Site

Seoul, , South Korea

Site Status

502.550.82005 Boehringer Ingelheim Investigational Site

Seoul, , South Korea

Site Status

502.550.82006 Boehringer Ingelheim Investigational Site

Seoul, , South Korea

Site Status

502.550.82007 Boehringer Ingelheim Investigational Site

Seoul, , South Korea

Site Status

502.550.82011 Boehringer Ingelheim Investigational Site

Seoul, , South Korea

Site Status

502.550.82012 Boehringer Ingelheim Investigational Site

Seoul, , South Korea

Site Status

502.550.82013 Boehringer Ingelheim Investigational Site

Seoul, , South Korea

Site Status

502.550.82004 Boehringer Ingelheim Investigational Site

Suwon, , South Korea

Site Status

502.550.82010 Boehringer Ingelheim Investigational Site

Wŏnju, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Bulgaria China France Georgia Romania Russia South Korea

References

Explore related publications, articles, or registry entries linked to this study.

Zhu DL, Bays H, Gao P, Mattheus M, Voelker B, Ruilope LM. Efficacy and tolerability of initial therapy with single-pill combination telmisartan/hydrochlorothiazide 80/25 mg in patients with grade 2 or 3 hypertension: a multinational, randomized, double-blind, active-controlled trial. Clin Ther. 2012 Jul;34(7):1613-24. doi: 10.1016/j.clinthera.2012.05.007. Epub 2012 Jun 19.

Reference Type DERIVED
PMID: 22717420 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2008-007711-32

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

502.550

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine
NCT01911780 COMPLETED PHASE3
Safety Evaluation of Telmisartan Plus Hydrochlorothiazide in Patients With Mild-to-Moderate Hypertension
NCT02177487 COMPLETED PHASE3
Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Failed in Telmisartan 80 mg
NCT00146341 COMPLETED PHASE3
Telmisartan Compared to Losartan + Hydrochlorothiazide in Patients With Mild-to-moderate Essential Hypertension
NCT02183701 COMPLETED PHASE3
Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension
NCT02269176 COMPLETED PHASE3
Telmisartan With or Without Hydrochlorothiazide (HCTZ) Compared With Losartan With or Without HCTZ in Mild to Moderate Hypertensive Patients
NCT02172586 COMPLETED PHASE4
Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan Monotherapy
NCT00144222 COMPLETED PHASE3
Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension
NCT00257491 COMPLETED PHASE3
Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension
NCT00860262 COMPLETED PHASE3
Telmisartan 80mg Non-responder Trial
NCT01222520 COMPLETED PHASE3
Study of Hypertensive Population Under Treatment With Telmisartan in Real Clinical Conditions With the Goal to Control Early Morning Blood Pressure Rise
NCT00946829 COMPLETED
Efficacy and Safety of Chronic Administration of Telmisartan as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension
NCT02177422 COMPLETED PHASE3
26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension
NCT00624052 COMPLETED PHASE3
Survey to Assess Why People Are Not Responding to Treatment in Hypertension
NCT01071681 COMPLETED
Relative Bioavailability of Telmisartan and HCTZ in Two Experimental Formulations Compared to the Standard Formulation Telmisartan and HCTZ in Healthy Female and Male Subjects
NCT02262572 COMPLETED PHASE1
Telmisartan and Hydrochlorothiazide Antihypertensive Treatment Study in High Sodium Intake Population
NCT02255253 COMPLETED NA
An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy
NCT01103960 COMPLETED PHASE3
Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension
NCT00558428 COMPLETED PHASE3
TELSYS - TELmisartan Effectiveness in Isolated SYStolic Hypertension Versus Systolic/Diastolic Hypertension Patients Aged 55 or Older
NCT02242877 COMPLETED
SMOOTH - Blood Pressure Control in Diabetic/Obese Patients
NCT00239538 COMPLETED PHASE4
Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH)
NCT02175355 COMPLETED PHASE3
Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension
NCT00281580 COMPLETED PHASE3
Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment
NCT02620163 COMPLETED PHASE3
An Observational Study to Investigate the Efficacy, Safety, Tolerability and the Effect on Quality of Life of Telmisartan (Micardis) and Telmisartan With HCTZ (Micardis Plus) in Patients With Hypertension
NCT00904215 COMPLETED
Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg)
NCT01286558 COMPLETED PHASE3